SGN-30 (Seattle genetics).

Article Details

Citation
Copy to clipboard

Schnell R, Borchmann P

SGN-30 (Seattle genetics).

Curr Opin Mol Ther. 2006 Apr;8(2):164-72.

PubMed ID
16610770 [ View in PubMed
]
Abstract

Seattle Genetics is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. Phase II trials in patients with Hodgkin's disease, anaplastic large cell lymphoma, and cutaneous lymphoma have been conducted in the U.S. and Europe.

DrugBank Data that Cites this Article

Drugs